TY - JOUR
T1 - 2021 update on MRD in acute myeloid leukemia
T2 - a consensus document from the European LeukemiaNet MRD Working Party
AU - Heuser, Michael
AU - Freeman, Sylvie D.
AU - Ossenkoppele, Gert J.
AU - Buccisano, Francesco
AU - Hourigan, Christopher S.
AU - Ngai, Lok Lam
AU - Tettero, Jesse M.
AU - Bachas, Costa
AU - Baer, Constance
AU - Béné, Marie-Christine
AU - Bücklein, Veit
AU - Czyz, Anna
AU - Denys, Barbara
AU - Dillon, Richard
AU - Feuring-Buske, Michaela
AU - Guzman, Monica L.
AU - Haferlach, Torsten
AU - Han, Lina
AU - Herzig, Julia K.
AU - Jorgensen, Jeffrey L.
AU - Kern, Wolfgang
AU - Konopleva, Marina Y.
AU - Lacombe, Francis
AU - Libura, Marta
AU - Majchrzak, Agata
AU - Maurillo, Luca
AU - Ofran, Yishai
AU - Philippe, Jan
AU - Plesa, Adriana
AU - Preudhomme, Claude
AU - Ravandi, Farhad
AU - Roumier, Christophe
AU - Subklewe, Marion
AU - Thol, Felicitas
AU - Loosdrecht, Arjan A. van de
AU - Reijden, Bert A. van der
AU - Venditti, Adriano
AU - Wierzbowska, Agnieszka
AU - Valk, Peter J. M.
AU - Wood, Brent L.
AU - Walter, Roland B.
AU - Thiede, Christian
AU - Döhner, Konstanze
AU - Roboz, Gail J.
AU - Cloos, Jacqueline
PY - 2021/12/30
Y1 - 2021/12/30
N2 - Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.
AB - Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that is used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization and harmonization of MRD in an ongoing manner and has updated the 2018 ELN MRD recommendations based on significant developments in the field. New and revised recommendations were established during in-person and online meetings, and a 2-stage Delphi poll was conducted to optimize consensus. All recommendations are graded by levels of evidence and agreement. Major changes include technical specifications for next-generation sequencing-based MRD testing and integrative assessments of MRD irrespective of technology. Other topics include use of MRD as a prognostic and surrogate end point for drug testing; selection of the technique, material, and appropriate time points for MRD assessment; and clinical implications of MRD assessment. In addition to technical recommendations for flow- and molecular-MRD analysis, we provide MRD thresholds and define MRD response, and detail how MRD results should be reported and combined if several techniques are used. MRD assessment in AML is complex and clinically relevant, and standardized approaches to application, interpretation, technical conduct, and reporting are of critical importance.
U2 - 10.1182/blood.2021013626
DO - 10.1182/blood.2021013626
M3 - Article
SN - 0006-4971
VL - 138
SP - 2753
EP - 2767
JO - Blood
JF - Blood
IS - 26
ER -